The Latest Cardiac and Vascular News
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective,…
First Patient Enrollment in AGILITY Study Begins Investigations of Safety and Effectiveness of BD Vascular Covered Stent for Treatment of PAD FRANKLIN LAKES, N.J., March 4, 2024 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company,…
SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today…
BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral GAAP and adjusted diluted […]
FRANKLIN LAKES, N.J., Feb. 15, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America’s Best Large Employers List 2023 by Forbes, furthering its progress against the company’s environmental, social and governance (ESG) strategy. “This recognition is a reflection […]
Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively Company raises […]
Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral Q4 GAAP and adjusted diluted EPS from continuing operations of $0.92 and $2.75, […]
Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventional segment FRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive […]
FRANKLIN LAKES, N.J., Aug. 8, 2022 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX) (the “Company” or “BD“) today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the “Securities” and each a “series“). Up to an Aggregate […]
Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as reported, 9.3% currency-neutral Worldwide COVID-only testing revenues of $76 million declined from $300 million in the prior year GAAP diluted EPS from continuing operations of $1.28; adjusted diluted EPS […]
